Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
- PMID: 36687436
- PMCID: PMC9853546
- DOI: 10.3389/fmed.2022.1082604
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with giant cell arteritis
Abstract
Objective: To provide clinical guidance to Norwegian Rheumatologists and other clinicians involved in diagnosing and treating patients with giant cell arteritis (GCA).
Methods: The available evidence in the field was reviewed, and the GCA working group wrote draft guidelines. These guidelines were discussed and revised according to standard procedures within the Norwegian Society of Rheumatology. The European Alliance of Associations for Rheumatology (EULAR) recommendations for imaging and treatment in large vessel vasculitis and the British Society for Rheumatology (BSR) guidelines for diagnostics and treatment in GCA informed the development of the current guidelines.
Results: A total of 13 recommendations were developed. Ultrasound is recommended as the primary diagnostic test. In patients with suspected GCA, treatment with high doses of Prednisolone (40-60 mg) should be initiated immediately. For patients with refractory disease or relapse, Methotrexate (MTX) should be used as the first-line adjunctive therapy, followed by tocilizumab (TCZ).
Conclusion: Norwegian recommendations for diagnostics and treatment to improve management and outcome in patients with GCA were developed.
Keywords: diagnosis; giant cell arteritis (GCA); guidelines; large vessel vasculitis; treatment.
Copyright © 2023 Haaversen, Brekke, Bakland, Rødevand, Myklebust and Diamantopoulos.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with Polymyalgia Rheumatica: a narrative review.BMC Rheumatol. 2024 Nov 4;8(1):58. doi: 10.1186/s41927-024-00422-6. BMC Rheumatol. 2024. PMID: 39490996 Free PMC article.
-
Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis.Scand J Rheumatol. 2019 Jul;48(4):259-265. doi: 10.1080/03009742.2019.1571223. Epub 2019 Mar 6. Scand J Rheumatol. 2019. PMID: 30838907
-
The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis.Reumatismo. 2022 Feb 7;73(4). doi: 10.4081/reumatismo.2021.1470. Reumatismo. 2022. PMID: 35130681
-
Validity of the EULAR recommendations on the use of ultrasound in the diagnosis of giant cell arteritis.RMD Open. 2022 Apr;8(1):e002120. doi: 10.1136/rmdopen-2021-002120. RMD Open. 2022. PMID: 35383122 Free PMC article.
-
What is new in imaging to assist in the diagnosis of giant cell arteritis and Takayasu's arteritis since the EULAR and ACR/VF recommendations?Front Med (Lausanne). 2024 Oct 31;11:1495644. doi: 10.3389/fmed.2024.1495644. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39544379 Free PMC article. Review.
Cited by
-
Vascular ultrasound as a follow-up tool in patients with giant cell arteritis: a prospective observational cohort study.Front Med (Lausanne). 2024 Jul 29;11:1436707. doi: 10.3389/fmed.2024.1436707. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39135716 Free PMC article.
-
Norwegian society of rheumatology recommendations on diagnosis and treatment of patients with Polymyalgia Rheumatica: a narrative review.BMC Rheumatol. 2024 Nov 4;8(1):58. doi: 10.1186/s41927-024-00422-6. BMC Rheumatol. 2024. PMID: 39490996 Free PMC article.
-
Diagnosing vasculitis with ultrasound: findings and pitfalls.Ther Adv Musculoskelet Dis. 2024 Jun 5;16:1759720X241251742. doi: 10.1177/1759720X241251742. eCollection 2024. Ther Adv Musculoskelet Dis. 2024. PMID: 38846756 Free PMC article. Review.
-
Chitinase‑3 like‑protein‑1: A potential predictor of cardiovascular disease (Review).Mol Med Rep. 2024 Oct;30(4):176. doi: 10.3892/mmr.2024.13300. Epub 2024 Aug 12. Mol Med Rep. 2024. PMID: 39129301 Free PMC article.
-
Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden.Front Immunol. 2023 May 25;14:1187584. doi: 10.3389/fimmu.2023.1187584. eCollection 2023. Front Immunol. 2023. PMID: 37304255 Free PMC article. Clinical Trial.
References
-
- Weyand CM, Goronzy JJ. Medium- and large-vessel vasculitis. N Engl J Med. (2003) 349:160–9. - PubMed
-
- Schmidt J, Warrington KJ. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management. Drugs Aging. (2011) 28:651–66. - PubMed
-
- Cantini F, Niccoli L, Storri L, Nannini C, Olivieri I, Padula A, et al. Are polymyalgia rheumatica and giant cell arteritis the same disease? Semin Arthritis Rheum. (2004) 33:294–301. - PubMed
Publication types
LinkOut - more resources
Full Text Sources